Introduction {#s0001}
============

Since December 2019, unexplained pneumonia, today known as a novel coronavirus (2019-nCoV), has been identified in several patients across multiple Wuhan city hospitals (Hubei Province, China). Within 2 months, the infection spread rapidly to other Countries and regions \[[@CIT0001],[@CIT0002]\]. Today (11 April 2020), the virus has spread to 212 countries around the world, infecting more than 1,607,467 people and causing more than 98,866 deaths \[[@CIT0003]\].

Coronavirus is a large family of viruses that cause illness ranging from the common cold to more severe diseases, such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. On 11 February 2020, the International Committee on Taxonomy of viruses issued a statement stating an official designation for the novel virus: "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) \[[@CIT0003]\].

Fever, dry cough, and fatigue are the main clinical manifestations of the disease. Many infected patients present with mild flu-like symptoms and recover quickly. Yet, in certain populations, especially the elderly, the virus may cause respiratory failure and even result in death. Therefore, early identification of risk factors for disease progression is helpful for early intervention in severe patients. Previous studies have suggested that the highest temperature, dyspnoea, respiratory rate, white blood cell count, neutrophil count, lymphocyte count, [d]{.smallcaps}-dimer, albumin, and procalcitonin are risk factors for ICU care in patients with coronavirus disease 2019 (COVID-19) \[[@CIT0004],[@CIT0005]\]. In this study, we retrospectively examined 101 laboratory-confirmed cases of COVID-19 admitted to our hospital between 21 January 2020 and 9 March 2020, so as to investigate the factors affecting the outcomes with the hope of improving the treatment and reducing mortality.

Methods {#s0002}
=======

Subjects {#s0003}
--------

We performed a retrospective study of clinical characteristics and risk factors for disease progression in laboratory-confirmed cases with COVID-19 hospitalized at Beijing YouAn hospitals (Capital Medical University, Beijing) between 21 January 2020 and 9 March 2020. All patients were evaluated and clinically typed upon admission, according to the "Diagnosis and Treatment Protocol for Novel Coronavirus Infection-Induced Pneumonia version 7 (trial)" \[[@CIT0006]\]. Specific clinical types included: (1) mild: mild clinical manifestation with no unusual imaging data; (2) common: fever, respiratory symptoms, pneumonia performance on X-ray or CT; (3) severe (meet any of the followings): (i) respiratory distress, RR ≥ 30/min; (ii) oxygen saturation ≤ 93% at rest state; (iii) arterial partial pressure of oxygen (PaO~2~)/fraction of inspiration O2 (FiO~2~) ≤ 300 mmHg, 1 mmHg = 0.133 kPa; (4) critically ill (meet any of the followings): (i) respiratory failure needs mechanical ventilation; (ii) shock; (iii) combined with other organ failure, patients need ICU monitoring and treatment.

All patients were divided into two groups: progression group and improvement group. The definition of the progression group: clinically advanced types; patients admitted to ICU; death during hospitalization. The improvement group: the clinical types remained unchanged or changed to a lighter type, and patients were discharged from the hospital.

Laboratory testing {#s0004}
------------------

Patients' pharyngeal swab specimens were collected for the SARS-CoV-2 viral nucleic acid detection using real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay. Influenza A virus, influenza B virus, respiratory syncytial virus, adenovirus, parainfluenza virus, enterovirus, human metapneumovirus, coxsackievirus, chlamydia, and mycoplasma were detected by collecting body fluid (nasopharyngeal swabs and sputum) samples. Laboratory variables were tested with conventional methods, including (i) routine blood tests: the numbers of leukocytes, lymphocytes, and neutrophil, haemoglobin, platelet; (ii) blood biochemistry: alanine transaminase, aspartate aminotransferase, total bilirubin, albumin, creatinine, creatine kinase, myoglobin, troponin; (iii) partial pressure of oxygen and oxygen saturation of blood; (iv) infection indices: procalcitonin and CRP.

Data collection {#s0005}
---------------

We reviewed the electronic medical records, laboratory findings, and chest X-ray data for all patients. Personal data, epidemiological data, comorbidities, clinical data, laboratory data, radiological data, treatment and outcomes data were obtained with standardized data collection forms from electronic medical records. Two researchers also independently reviewed the data collection forms to double-check the collected data.

Statistical analysis {#s0006}
--------------------

Categorical variables were described as frequency rates and percentages, analyzed using the Chi-squared test or Fisher's exact test. Continuous variables were described using mean, median, and interquartile range (IQR) values. Means for continuous variables were compared using independent group *t*-tests when the data were normally distributed; otherwise, the Mann--Whitney *U* test was used. Univariate and multivariate analyses of prognostic factors were performed using the logistics regression. SPSS software version 20.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. The area under curve (AUC), cut-off value, sensitivity, and specificity of ROC were analyzed by the receiver operator characteristic curve (ROC). *p* \< .05 was considered statistically significant, and all *p* values were two-tailed.

Ethical approval {#s0007}
----------------

This study was conducted in accordance with the Declaration of Helsinki. The requirement for written informed consent was waived, given the context of emerging infectious diseases.

Results {#s0008}
=======

Demographics and case grouping {#s0009}
------------------------------

The study population included 101 hospitalized patients with laboratory-confirmed COVID-19, and 44 (43.6%) were men. The median age was 50.9 ± 20.1 years, and 27 patients were aged ≥65 years (26.7%). Among the 101 patients, there were 4 patients with the mild type (4.0%), 75 patients with the common type (74.3%), 13 patients with the severe type (12.9%), and nine patients with the critically ill type (8.9%) at admission.

Among the 101 patients, 8 cases with common type showed progression of the disease, 5 of them developed a severe type, while 3 progressed to critically ill type. Three cases with severe type progressed to critically ill type, and 6 cases with the critically ill type required ICU treatment after admission during hospitalization. A total of 17 patients (16.8%) were included in the progression group and 84 patients (83.2%) in the improvement group.

In the improvement group, 4 cases were with mild type, 67 cases with common type, 10 cases with severe type, and 3 cases with critically ill type. All of them were successfully discharged. Changes in conditions and outcomes of 101 patients after admission are shown in [Figure 1](#F0001){ref-type="fig"}.

![The change in condition and outcomes of 101 patients after admission. Among the 101 patients, 8 cases with common type showed progression of the disease, 5 of them developed a severe type, while 3 progressed to critically ill type. Three cases with severe type progressed to critically ill type, and 6 cases with the critically ill type required ICU treatment after admission during hospitalization. A total of 17 patients (16.8%) were included in the progression group and 84 patients (83.2%) in the improvement group. ICU: intensive care unit; \*included in the progression group.](INFD_A_1759817_F0001_C){#F0001}

Clinical characteristics {#s0010}
------------------------

Among these patients, 43 (42.6%) were in Hubei province during the virus outbreak, 78 (77.2%) clustering onset. The median duration from the first symptoms to diagnosis was 4.8 ± 2.9 days. Of the 101 patients, 30 (29.7%) had one or more comorbidities. Hypertension \[21(20.8%)\], cardiovascular disease \[11(10.9%)\], diabetes \[6(5.9%)\], and malignancy \[5 (5.0%)\] were the most common comorbidities. The most common symptoms were fever \[74 (73.3%)\] and dry cough \[63 (62.4%)\]. The median Sequential Organ Failure Assessment (SOFA) score was 1 (IQR, 0--1).

The patients in the progression group were significantly older than those in the improvement group (72.4 ± 13.9 versus 46.6 ± 18.3). There was no significant difference in sex between the two groups (*p* \> .05). Compared with the improvement group, the patients in the progression group were more likely to have underlying comorbidities (58.8% versus 23.8%*, χ^2^* = 8.301, *p* = .004). Besides, the progression group had a significantly higher proportion of patients with hypertension than the improvement group (47.1% versus 15.5%, *χ^2^* = 6.753, *p* = .009). There was no significant difference in other comorbidities.

The maximum body temperature, heart rate, mean arterial pressure, and blood oxygen saturation did not differ between patients in the progression and improvement group. The respiratory rate in the progression group was significantly higher than in the improvement group (21.0 ± 2.0 breaths/min versus 20.0 ± 1.7 breaths/min, *t* = --2.072, *p* = .041). The median SOFA scores in the progression group were significantly higher than those in the improvement group \[3(1.5, 4) versus 3(0, 1), *U* = 6.175, *p* \< .001\]. Demographic data and clinical characteristics of 101 patients with COVID-19 are shown in [Table 1](#t0001){ref-type="table"}.

###### 

Demographic data and clinical characteristics of 101 patients with COVID-19.

  -------------------------------------------------------------------------------------------------------------------------------------------
                                                               Total\          Improvement\    Progression\    *t/U/χ^2^* value   *p* Value
                                                               *n* = 101       *n* = 84        *n* = 17                           
  ------------------------------------------------------------ --------------- --------------- --------------- ------------------ -----------
  Age (years, mean ± S.D.)                                     50.9 ± 20.1     46.6 ± 18.3     72.4 ± 13.9     −5.496              \<.001

  Gender (male/female)                                         44/57           34/50           10/7            1.936              .164

  History of exposure to Hubei province (*n*, %)               43 (42.6)       37 (44.0)       6 (35.3)        0.443              .506

  Cluster (*n*, %)                                             78 (77.2)       63 (75.0)       15 (88.2)       0.756              .385

  Duration from first symptoms to diagnosis (d, mean ± S.D.)   4.8 ± 2.9       4.7 ± 2.7       5.2 ± 3.6       −0.600             .550

  Comorbidities (*n*, %)                                       30 (29.7)       20 (23.8)       10 (58.8)       8.301              .004

   Hypertension                                                21 (20.8)       13 (15.5)       8 (47.1)        6.753              .009

   Coronary artery disease                                     11 (10.9)       7 (8.3)         4 (23.5)        1.981              .159

   Diabetes mellitus                                           6 (5.9)         4 (4.8)         2 (11.8)        0.304              .581

   Cerebrovascular                                             3 (3.0)         2 (2.4)         1 (5.9)         0.595              .428

   Chronic obstructive pulmonary disease                       4 (4.0)         2 (2.4)         2 (11.8)        3.241              .131

   Malignancy                                                  5 (5.0)         4 (4.8)         1 (5.9)         0.038              .846

  Symptoms (*n*, %)                                                                                                               

   Fever                                                       74 (73.3)       59 (70.2)       15 (88.2)       1.510              .219

   Dry cough                                                   63 (62.4)       53 (63.1)       10 (58.8)       0.110              .740

  Temperature max (°C, mean ± S.D.)                            38.5 ± 0.6      38.5 ± 0.6      38.6 ± 0.5      --0.849            .399

  Respiratory rate (breaths/min, mean ± S.D.)                  20.2 ± 1.8      20.0 ± 1.7      21.0 ± 2.0      −2.072             .041

  Heart rate (beats/min, mean ± S.D.)                          85.5 ± 12.8     85.6 ± 12.5     84.9 ± 14.5     0.188              .851

  Mean arterial pressure (mmHg, mean ± S.D.)                   89.7 ± 13.8     90.8 ± 10.4     84.7 ± 24.4     1.678              .097

  Blood oxygen saturation (%, mean ± S.D.)                     96.5 ± 4.0      96.8 ± 3.0      95.3 ± 7.1      1.376              .172

  SOFA (median, IQR)                                           1.0 (0.0,1.0)   0.0 (0.0,1.0)   3.0 (1.5,4.0)   6.157              \<.001
  -------------------------------------------------------------------------------------------------------------------------------------------

SOFA: Sequential Organ Failure Assessment.

Laboratory findings and imaging characteristics {#s0011}
-----------------------------------------------

Laboratory indices of the 101 patients with COVID-19 were determined at the time of admission. There were numerous differences in laboratory data between patients in the progression group and the improvement group ([Table 2](#t0002){ref-type="table"}). White blood cell count and neutrophil count were significantly elevated, and lymphocyte count significantly decreased in the progression group compared to the improvement group. Albumin was significantly decreased in the progression group compared to the improvement group. In addition, the levels of estimated glomerular filtration rate, creatine kinase isoenzymes, myoglobin, troponin, C-reactive protein, procalcitonin, and lactic acid were significantly increased in the progression group compared to the improvement group. Eighty-seven out of 101 enrolled patients showed bilateral involvement of chest CT scan, and 10 patients showed unilateral involvement. There were no significant differences in imaging findings between the two groups ([Table 2](#t0002){ref-type="table"}).

###### 

Laboratory results and imaging findings of 101 patients with COVID-19.

  --------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Total\                Improvement\          Progression\          *t/U/χ^2^* value   *p* Value
                                                    *n* = 101             *n* = 84              *n* = 17                                 
  ------------------------------------------------- --------------------- --------------------- --------------------- ------------------ -----------
  Laboratory results (mean ± S.D. or median, IQR)                                                                                        

   WBC (× 10^9^/L)                                  4.3 (3.5,5.8)         4.1 (3.5,5.6)         6.4 (3.7,8.2)         2.360              .018

   N (× 10^9^/L)                                    2.6 (1.8,3.8)         2.3 (1.8,3.3)         4.9 (2.7,7.3)         3.556              \<.001

   L (× 10^9^/L)                                    1.2 ± 0.8             1.3 ± 0.8             0.7 ± 0.3             3.205              .002

   PLT (× 10^9^/L)                                  192.1 (156.2,245.8)   192.2 (158.8,248.8)   193.5 (111.4,218.5)   −1.002             .316

   ALT (U/L)                                        28.3 (20.0,46.70)     28.6 (20.5,45.3)      36.2 (18.4,63.1)      0.743              .458

   AST (U/L)                                        30.3 (22.5,45.6)      30.5 (22.6,42.8)      37.8 (22.5,76.4)      1.569              .117

   TBIL (μmol/L)                                    9.2 (6.6,12.4)        8.9 (6.4,12.0)        12.1 (7.6,15.6)       1.633              .102

   ALB (g/L)                                        35.8 ± 5.8            36.5 ± 5.2            32.3 ± 7.2            2.793              .006

   Cr (umol/L)                                      64.3 (53.5,77.8)      62.9 (53.1,74.8)      77.3 (54.5,88.1)      1.680              .093

   eGFR                                             99.5 (89.0,114.7)     105.3 (94.0,118.8)    91.2 (66.7,96.9)      −3.512             \<.001

   CK (U/L)                                         80.5 (46.0,130.3)     74.5 (45.8,122.3)     96.0 (59.7,161.3)     1.105              .269

   CKMB (U/L)                                       0.3 (.02,0.9)         0.3 (0.2,0.6)         1.1 (0.3,2.5)         2.919              .004

   MYO (ng/ml)                                      44.5 (30.0,67.5)      36.5 (28.2,59.4)      97.4 (52.3,198.5)     3.755              \<.001

   TNI (ng/ml)                                      0.01 (0.01,0.02)      0.01 (0.01,0.02)      0.04 (0.01,0.08)      3.306              .001

   PT (s)                                           12.6 (11.9,13.1)      12.6 (12.0,13.1)      12.8 (11.6,13.6)      0.164              .869

   INR                                              1.1 (1.1,1.2)         1.1 (1.1,1.2)         1.1 (1.0,1.2)         0.052              .959

   CRP (mg/L)                                       19.3 (3.6,59.1)       13.9 (2.6,26.9)       86.0 (66.7,122.5)     5.312              \<.001

   PCT (ng/ml)                                      0.1 (0.1,0.1)         0.1 (0.1,0.1)         0.1 (0.1,0.2)         2.944              .003

   LAC (mmol/L)                                     1.3 ± 0.6             1.3 ± 0.5             1.7 ± 0.8             −2.946             .004

  Imaging findings (*n*, %)                                                                                                              

   Normal                                           4 (4.0)               4 (4.8)               0 (0)                 0.056              .813

   Unilateral involvement                           10 (10.0)             10 (11.9)             0 (0)                 1.110              .292

   Bilateral involvement                            87 (86.1)             70 (83.3)             17 (100.0)            2.041              .153
  --------------------------------------------------------------------------------------------------------------------------------------------------

WBC: white blood cell count; N: neutrophil count; L: lymphocyte count; PLT: platelet count; ALT: alanine transaminase; AST: aspartate transaminase; TBIL: total bilirubin; ALB: albumin; Cr: creatinine; CK: creatinine kinase; CKMB: creatine kinase isoenzymes; MYO: myoglobin; TNI: troponin; PT: prothrombin time; INR: international normalized ratio; CRP: C-reactive protein; PCT: procalcitonin; LAC: lactic acid.

Treatments, complications and outcomes {#s0012}
--------------------------------------

The main treatments, complications, and outcomes are shown in [Table 3](#t0003){ref-type="table"}. Of the 101 patients, 35 (34.7) patients received antiviral therapy. The proportion of systemic corticosteroid treatment and human-immunoglobulin treatment in the progression group was significantly higher than that in the improvement group (82.3% versus 21.4%; 35.3% versus 1.2%). The proportion of patients in the progression group who required ICU care, continuous renal replacement therapy (CRRT), invasive mechanical ventilation, and extracorporeal membrane oxygenation (ECMO) treatment were 58.8%, 29.4%, 41.2%, and 23.5%, respectively.

###### 

Treatments, complications and outcomes of 101 patients with COVID-19.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                               Total\              Improvement\        Progression\        *t*/*U*/*χ*^2^ value   *p* Value
                                                               *n* = 101           *n* = 84            *n* = 17                                   
  ------------------------------------------------------------ ------------------- ------------------- ------------------- ---------------------- -----------
  Treatments (*n*, %)                                                                                                                             

   Antiviral treatment                                         35 (34.7)           29 (34.5)           6 (35.3)            0.004                  .951

   Systemic corticosteroid treatment                           32 (31.7)           18 (21.4)           14 (82.3)           24.246                 \<.001

   Human-immunoglobulin                                        7 (6.9)             1 (1.2)             6 (35.3)            20.480                 \<.001

   ICU care                                                    10 (10.0)           0 (0)               10 (58.8)           48.446                  \<.001

   CRRT                                                        5 (5.0)             0 (0)               5 (29.4)            20.118                 \<.001

   Oxygen support                                                                                                                                 

    Nasal cannula                                              63 (62.4)           46 (54.8)           17 (100.0)          12.329                 \<.001

    Non-invasive ventilation or high-flow nasal cannula        3 (3.0)             0 (0)               3 (17.6)            9.768                  .002

    Invasive mechanical\                                       7 (6.9)             0 (0)               7 (41.2)            31.054                 \<.001
  ventilation                                                                                                                                     

    Invasive mechanical\                                       4 (4.0)             0 (0)               4 (23.5)            14.858                 .001
  ventilation and ECMO                                                                                                                            

  Complications (*n*, %)                                                                                                                          

   Acute Respiratory Distress Syndrome                         7 (6.9)             0 (0)               7 (41.2)            31.054                  \<.001

   Sepsis                                                      7 (6.9)             1 (1.2)             6 (35.3)            20.480                  \<.001

   Septic shock                                                6 (5.9)             0 (0)               6 (35.3)            25.520                  \<.001

   Cardiogenic shock                                           3 (3.0)             0 (0)               3 (17.6)            9.768                  .002

   Arrhythmia                                                  7 (6.9)             0 (0)               7 (41.2)            31.054                  \<.001

   Myocardial injury                                           24 (23.8)           10 (11.9)           14 (82.3)           34.942                  \<.001

   Acute kidney injury                                         12 (11.9)           6 (7.1)             6 (35.3)            8.182                  .004

   Liver injury                                                38 (37.6)           28 (33.3)           10 (58.8)           3.914                  .048

   Secondary infection                                         9 (8.9)             1 (1.2)             8 (47.1)            31.242                  \<.001

  Outcomes (*n*, % or mean ± S.D.)                                                                                                                

   Time taken for temperature normalization (d)                8.6 ± 4.3           8.0 ± 3.8           11.3 ± 5.4          −2.798                 .006

   Time required to obtain negative nucleic acid results (d)   12.5 ± 5.0          11.7 ± 4.4          17.2 ± 5.9          −4.246                  \<.001

   Time taken for imaging improvement (d)                      14.9 ± 5.4          14.0 ± 3.2          22.8 ± 11.3         −2.319                 .048

   Improved and discharged (*n*)                               93 (92.1)           84 (100.0)          9 (52.9)            26.827                  \<.001

    Death (*n*)                                                5 (5.0)             0 (0)               5 (29.4)            20.118                  \<.001

   Length of hospital stay \[d, (median, IQR)\]                13.0 (10.0, 17.0)   13.0 (10.0, 16.0)   20.5 (15.3, 22.3)   3.065                  .002
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; CRRT: continuous renal replacement therapy.

Seven out of 101 patients (6.9%) developed acute respiratory distress syndrome (ARDS). Seven patients were complicated with sepsis; six of them developed into septic shock. Cardiogenic shock and arrhythmia were found in 3 patients and seven patients, respectively. The proportion of myocardial injury, acute renal injury, and liver injury was 23.8%, 11.9%, and 37.6%, respectively. Nine patients developed a secondary bacterial infection. The rate of secondary bacterial infection in the progression group was 47.1%, which was significantly higher than that in the improvement group (1.2%).

The mean time for the body temperature to decrease was 8.6 ± 4.3 days, the mean time to obtain negative nucleic acid result was 12.5 ± 5.0 days, and the mean time for imaging improvement was 14.9 ± 5.4 days. Compared with the improvement group, the body temperature decreased more slowly, and negative nucleic acid results and imaging improvements were achieved later in patients from progression group (11.3 ± 5.4 versus 8.0 ± 3.8; 17.2 ± 5.9 versus 11.7 ± 4.4; 22.8 ± 11.3 versus 14.0 ± 3.2 days). The mortality in these patients was 5%, and the median hospital stay was 13 days (IQR, 10.0--17.0).

Risk factors for disease progression {#s0013}
------------------------------------

The results of the univariate logistic analysis found that age, comorbidities, neutrophil count, lymphocyte count, albumin, myoglobin, and CRP were significantly associated with the disease progression. Furthermore, the multivariate logistic analysis indicated that age (OR, 0.104; 95% CI: 0.024--0.449; *p* = .002), CRP (OR, 0.093; 95% CI: 0.025--0.314; *p \< *.001) and lymphocyte count (OR, 3.397; 95% CI: 1.195--9.565; *p* = .022) were risk factors for disease progression ([Table 4](#t0004){ref-type="table"}). ROC curve analysis revealed that the AUC of age, CRP and lymphocyte count for disease progression were 0.873 (95% CI: 0.786--0.961, *p* \< .001), 0.911 (95% CI: 0.843--0.978, *p* \< .001), 0.817 (95% CI: 0.711--0.923, *p* \< .001), respectively ([Figure 2](#F0002){ref-type="fig"}). Age \> 62.5 years, CRP \> 51.4 mg/L and lymphocyte count \< 0.945 × 109/L indicated the progression of the disease, where the sensitivity was 82.4%, 94.1.2% and 94.1%, and the specificity was 79.3%, 85.4% and 68.3%.

![ROC curve of independent risk factors for disease progression in patients with COVID-19.](INFD_A_1759817_F0002_C){#F0002}

###### 

Logistic analysis results of risk factors for disease progression (*n* = 101).

                                 *B*      OR        *p* Value   95% CI
  ------------------------------ -------- --------- ----------- --------------
  Age (years)                                                   
    \<60                                  1 (ref)                
   ≥60                           −2.267   0.104     .002        0.024--0.449
  CRP (mg/L)                                                    
    \<60                                  1 (ref)                
   ≥60                           −2.373   0.093     \<.001      0.025--0.341
  Lymphocyte count (× 10^9^/L)                                  
    \<1.1                                 1 (ref)                
   ≥1.1                          1.223    3.397     .022        1.195--9.565

OR: odds ratio; CRP: C-reactive protein.

Discussion {#s0014}
==========

In this retrospective cohort study, 17 patients (16.8%) developed disease progression after admission; 6 were transferred to ICU, and five (4.9%) patients died. Similar data were reported in the recent meta-analysis that examined 50466 cases with SARS-CoV-2 \[[@CIT0007]\].

This study identified several risk factors for disease progression in patients who were hospitalized with COVID-19 in Beijing. In particular, older age, higher CRP, and lower lymphocyte count on admission were associated with higher odds of in-hospital disease progression. Additionally, more comorbidities, elevated levels of white blood cell count, myoglobin, troponin, and decreased levels of albumin were more commonly seen in patients with disease progression. In addition, the time to obtain negative nucleic acid results was significantly longer in patients with disease progression compared to those who showed improvement.

Coronaviruses are a large family of viruses found in several domestic animals, pets, and humans, causing a variety of acute and chronic diseases \[[@CIT0008]\]. Currently, the pathogenesis of the COVID-19 still remains unclear, and there is no precise and effective treatment. Recent clinical research suggests that some patients have mild symptoms and can recover quickly, while others may develop rapid disease progression, which often leads to respiratory failure and even death. Besides, advanced age at presentation has shown to be very useful in predicting the mortality in SARS \[[@CIT0009]\] and MERS \[[@CIT0010]\] cases. Elderly patients tend to develop a greater number of comorbidities, potentially leading to poor outcomes \[[@CIT0011]\]. Besides, studies have shown that older macaques have stronger host innate responses to virus infection than younger adults, which promotes inflammation \[[@CIT0012]\]. The current study confirmed that increased age was associated with disease progression in patients with COVID-19.

CRP is an important inflammatory index and a significant predictor of disease progression. Previous studies on SARS have suggested the initial CRP level as a predictive factor of death \[[@CIT0013]\]. Rapid elevation of inflammatory cytokines-IL-6, IL-8, and TNF-alpha might have a role in the development of SARS-related ARDS. The timing of elevations in inflammatory cytokines and CRP is correlated with the progression of pulmonary infiltrates of SARS patients \[[@CIT0014]\]. In addition, studies have found that CRP is one of the risk factors for disease progression in Wuhan patients with COVID-19 \[[@CIT0015]\]. Moreover, lymphocyte count is another predictor of disease progression. The most common laboratory abnormalities observed across several studies were depressed total lymphocytes \[[@CIT0016]\]. Recently, it has been found that the number of CD4 and CD8 T cells in the peripheral blood of patients with COVID-19 is significantly reduced, but the state is over-activated, which shows the increase of Th17 and the high cytotoxicity of CD8 T cells thus suggesting serious damage of immune system in these patients \[[@CIT0016]\]. Our study confirmed that CRP and lymphocytopenia were independent risk factors for disease progression.

Our study also found that patients with disease progression were more likely to have various complications, especially cardiac complications. The incidence of cardiogenic shock and arrhythmia in patients with disease progression was significantly higher than that in the improvement group. Moreover, the incidence of myocardial injury, including an abnormal increase of creatine kinase isoenzymes (CKMB) and/or troponin (TnI) was significantly higher than that of the improvement group. The previous study reported an incidence of acute cardiac injury of 7.2--12% in Wuhan patients with COVID-19 \[[@CIT0017],[@CIT0018]\], which was lower than our results (23.8%). In addition, ARDS, secondary infection, sepsis and septic shock, kidney injury, and liver injury also resulted as related to disease progression.

Compared with the improvement group, the body temperature decreased more slowly in patients from the progression group (11.3 ± 5.4 versus 8.0 ± 3.8). Besides, detectable SARS-CoV-2 RNA persisted for a mean of 17.2 ± 5.9 days in the progression group, which was significantly longer compared to the disease improvement group (11.7 ± 4.4 days). Therefore, it is critical for these patients to receive effective antiviral treatment as early as possible \[[@CIT0019]\]. Currently, there are no FDA-approved treatments for human CoV infection; however, there are agents that have shown to be effective for SARS and MERS epidemics, such as Lopinavir and Ritonavir \[[@CIT0020],[@CIT0021]\].

Our study has few limitations. First, our sample size was relatively small, which may lead to biased results. Consequently, a multi-center large-scale study is required. Second, not all patients underwent laboratory testing, such as detecting lactate dehydrogenase and cytokine levels, so they were not included in the risk factor analysis.

In conclusion, patients with COVID-19 showed similar clinical manifestations to those with MERS or SARS. Older age, CRP, and lymphocyte count at admission were identified as risk factors for disease progression in patients with COVID-19 and may be useful for identifying an early-stage disease. Effective antiviral therapy may improve the patients' outcomes.
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